文献速递脑血管病

替奈普酶与阿替普酶在常规临床实践中的前瞻性观察性队列研究

Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice.
PubMed 文献 · Stroke · 2022-09-23

美国10家医院区域网络于2019年9月将卒中溶栓药物改为替奈普酶。该前瞻性登记队列比较替奈普酶组234例与阿替普酶组354例,发现替奈普酶组到院至给药时间及转诊到院至离院时间达标率更高,出院良好结局不劣于阿替普酶,住院费用更低。

要点

  • 替奈普酶组45分钟内到院至给药达标率41%高于阿替普酶组29%,校正OR 1.85。
  • 替奈普酶组90分钟内转诊到院至离院达标率37%(15/43)高于阿替普酶组14%(9/65)。
  • 替奈普酶组每次住院中位费用13382美元低于阿替普酶组15841美元。

核心结论

  • 在10家医院区域网络的常规临床实践中改用替奈普酶与更短的到院至给药时间和转诊到院至离院时间相关,出院良好临床结局不劣于阿替普酶,并降低住院费用。
  • 作者建议在更大规模的多中心队列中评估这些观察结果能否推广。

研究设计与样本

  • 前瞻性登记为基础的观察性序贯队列比较,比较替奈普酶组(n=234)与阿替普酶组(n=354)卒中患者。
  • 研究假设为替奈普酶组达到目标到院至给药时间和转诊到院至离院时间目标时间的患者比例增加,且良好与不良临床结局不劣于阿替普酶。
  • 同时比较两种治疗相关的住院总费用。

主要发现

  • 全部患者45分钟内到院至给药达标率替奈普酶组41% vs 阿替普酶组29%,校正OR 1.85(95%CI 1.27-2.71),P=0.001;按Get With The Guidelines标准为58% vs 41%。
  • 90分钟内转诊到院至离院达标率替奈普酶组37%(15/43) vs 阿替普酶组14%(9/65),校正OR 3.62(95%CI 1.30-10.74),P=0.02。
  • 良好结局(出院回家并可独立行走)替奈普酶组落在6.5%非劣效界值内,校正OR 1.26(95%CI 0.89-1.80)。
  • 不良结局(症状性颅内出血、院内死亡或出院转临终关怀)替奈普酶组7.3% vs 阿替普酶组11.9%,校正OR 0.77(95%CI 0.42-1.37),但未落在预设的1%非劣效界值内。
  • 净获益(良好结局百分比减不良结局百分比)替奈普酶组37% vs 阿替普酶组27%,P=0.02;每次住院中位费用替奈普酶组13382美元 vs 阿替普酶组15841美元,P<0.001。

关键数值与推荐

  • 45分钟内到院至给药达标率:替奈普酶组41% vs 阿替普酶组29%,校正OR 1.85(95%CI 1.27-2.71),P=0.001。
  • 90分钟内转诊到院至离院达标率:替奈普酶组37%(15/43) vs 阿替普酶组14%(9/65),校正OR 3.62(95%CI 1.30-10.74),P=0.02。
  • 良好结局:替奈普酶组校正OR 1.26(95%CI 0.89-1.80),落在6.5%非劣效界值内。
  • 不良结局:替奈普酶组7.3% vs 阿替普酶组11.9%,校正OR 0.77(95%CI 0.42-1.37),未落在预设的1%非劣效界值内。
  • 每次住院中位费用:替奈普酶组13382美元 vs 阿替普酶组15841美元,P<0.001。

临床怎么用

  • 作者建议在更大规模的多中心队列中评估这些观察结果能否推广。

局限性

  • 作者建议在更大规模的多中心队列中评估这些观察结果能否推广。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A 10-hospital regional network transitioned to tenecteplase as the standard of care stroke thrombolytic in September 2019 because of potential workflow advantages and reported noninferior clinical outcomes relative to alteplase in meta-analyses of randomized trials. We assessed whether tenecteplase use in routine clinical practice reduced thrombolytic workflow times with noninferior clinical outcomes. METHODS: We designed a prospective registry-based observational, sequential cohort comparison of tenecteplase- (n=234) to alteplase-treated (n=354) stroke patients. We hypothesized: (1) an increase in the proportion of patients meeting target times for target door-to-needle time and transfer door-in-door-out time, and (2) noninferior favorable (discharge to home with independent ambulation) and unfavorable (symptomatic intracranial hemorrhage, in-hospital mortality or discharge to hospice) in the tenecteplase group. Total hospital cost associated with each treatment was also compared. RESULTS: Target door-to-needle time within 45 minutes for all patients was superior for tenecteplase, 41% versus 29%; adjusted odds ratio, 1.85 (95% CI, 1.27-2.71); P=0.001; 58% versus 41% by Get With The Guidelines criteria. Target door-in-door-out time within 90 minutes was superior for tenecteplase 37% (15/43) versus 14% (9/65); adjusted odds ratio, 3.62 (95% CI, 1.30-10.74); P=0.02. Favorable outcome for tenecteplase fell within the 6.5% noninferiority margin; adjusted odds ratio, 1.26 (95% CI, 0.89-1.80). Unfavorable outcome was less for tenecteplase, 7.3% versus 11.9%, adjusted odds ratio, 0.77 (95% CI, 0.42-1.37) but did not fall within the prespecified 1% noninferior boundary. Net benefit (%favorable-%unfavorable) was greater for the tenecteplase sample: 37% versus 27%. P=0.02. Median cost per hospital encounter was less for tenecteplase cases ($13 382 versus $15 841; P<0.001). CONCLUSIONS: Switching to tenecteplase in routine clinical practice in a 10-hospital network was associated with shorter door-to-needle time and door-in-door-out times, noninferior favorable clinical outcomes at discharge, and reduced hospital costs. Evaluation in larger, multicenter cohorts is recommended to determine if these observations generalize.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Warach SJ, Dula AN, Milling TJ, et al. Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice. Stroke. 2022. PMID: 36148657. doi:10.1161/STROKEAHA.122.038950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。